 PHILADELPHIA, July 20, 2021 GLOBE NEWSWIRE -- AnPac Bio-Medical Science Co., Ltd. AnPac Bio, the Company or we NASDAQ: ANPC, a biotechnology company with operations in China and the United States focused on early cancer screening and detection as well as cancer treatment, pre-announced today that it has experienced strong growth in test volume in the first half year of 2021, with total number of paid customers and testing volume increasing almost 110 compared with the same period in 2020. In addition, in Q2 of this year, the Companys total paid tests and paid cancer tests increased approximately 280 and approximately 270, respectively quarter over quarter. In addition to paid cancer tests, other tests including new test products launched in 2020 have also grown. 